Windlas Biotech Ltd

Windlas Biotech Announces ₹47 Crore Share Buyback 📈

• Buyback of 470,000 equity shares at ₹1,000 per share, totaling ₹47 crore

• Represents 2.23% of total paid-up equity capital and 9.80% of capital + free reserves

• Buyback price offers a premium of 22.82% to 32.97% over recent market prices

• Record date for eligibility: April 24, 2026

• Tendering period: April 30 to May 7, 2026 (excluding May 1)

• Buyback ratio: 1 share for every 18 shares held

• Small shareholders (≤232 shares) allocated 97,342 reserved shares

• Promoters (holding 61.90%) will not participate

• Post-buyback, promoter shareholding expected to increase to 63.31%

• EPS expected to rise from ₹29.19 to ₹29.86; ROE from 12.76% to 14.16%

• Funding from free reserves—no borrowed funds used

• Debt-equity ratio remains compliant at 0.06 post-buyback

• No further capital raising planned for one year after buyback completion (except ESOP conversions)